Patient-reported symptom relief from the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

Patient satisfaction with tildrakizumab treatment in the Week 28 interim analysis of a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis

Efficacy and safety of 1% clascoterone cream through 12 weeks in patients ≥12 years of age with facial acne vulgaris: pooled data analyses of two Phase 3 randomized clinical trials

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor major adverse cardiovascular events (MACE) and venous thromboembolic events (VTEs) in the phase 3 POETYK PSO-1, PSO‑2, and long-term extension (LTE) trials ​ 

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: Malignancies in the Phase 3 POETYK PSO-1, PSO-2, and Long-term Extension (LTE) Trials

Long-Term Safety of Risankizumab in Patients With Psoriatic Disease: Findings From Integrated Analyses of 17 Clinical Trials in Psoriasis and 4 in Psoriatic Arthritis

Long-term Efficacy and Safety of Risankizumab (RZB) for the Treatment of Moderate to-Severe Plaque Psoriasis: Interim Analysis of Results From the LIMMitless Open-label Extension Trial Beyond 4 Years

Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

​Tralokinumab treatment substantially improves patient-reported outcomes in adolescents with moderate-to-severe atopic dermatitis at 16 weeks

COVID-19 in tralokinumab-treated patients with moderate-to-severe atopic dermatitis: case series from the ECZTEND long-term extension trial

Long-term treatment with tralokinumab normalizes the molecular gene signature of atopic dermatitis

Efficacy and safety of tralokinumab plus topical corticosteroids in patients with severe atopic dermatitis and prior history of dupilumab treatment: a post hoc subgroup analysis from ECZTRA 7 trial

Efficacy and Safety of Dupilumab in Children Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis

Dupilumab treatment restores skin barrier function and improves clinical and patient reported outcomes in adults and adolescents with moderate to severe atopic dermatitis

Dupilumab Provides Long-Term Improvement in Sleep Loss in Children, Adolescents, and Adults With Atopic Dermatitis

Efficacy and Safety of Dupilumab in Children Aged 6–11 Years with Inadequately Controlled Severe Atopic Dermatitis: Results From an Open-Label Extension Trial up to 1 Year

Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials